Beta Bionics, Inc. — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Beta Bionics reported Q3 2026 net sales of $35.5M (up 30% YoY), with PBP channel sales surging 118% to $13.6M. The company completed a public stock offering raising ~$161.3M net proceeds and announced FDA clearance of its Mint disposable system for Q1 2027 launch. However, net loss widened to $24.4M (vs. $14.2M YoY) and adjusted EBITDA deteriorated to negative $18.9M; the company withdrew its 3D Intelligence 510(k) application, resubmitting in mid-Q4 2026. Full-year 2026 guidance raised to $124–126M (from $121–126M), but cites potential $8.5M Q4 revenue deferral as customers await Mint launch.
Why this rating
Strong revenue growth and Mint FDA clearance are operationally positive; $161M capital raise substantially strengthens balance sheet (36% of market cap). However, widening losses, 3D Intelligence regulatory setback, anticipated Q4 revenue deferral, and commercial execution risk on new products temper outlook. Moderate significance: material financing and pipeline progress, but pre-profitability company still years from sustainable operations.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.